Sign In
Free Newsletter
Bristol Myers Squibb inks $15.2B drug deal with Hengrui
The partnership with Hengrui Pharma will develop 13 oncology, hematology and immunology drug programs worldwide.
Bayer to buy Perfuse Therapeutics for up to $2.45B
Bayer is planning a $2.45B acquisition of Perfuse Therapeutics to boost its ophthalmology pipeline with an eye disease treatment.
Novartis to buy Excellergy for $2B to boost allergy drugs
Novartis will acquire the California biotech, adding next-gen IgE therapy Exl-111 to its portfolio in the first half of 2026.
Merck to acquire Terns Pharmaceuticals in $6.7B oncology deal
Merck's addition of Terns Pharmaceuticals will help expand the buyer's pipeline ahead of the expiration for its Keytruda patent in 2028.
Novartis to acquire Synnovation’s breast cancer drug for $2B
The addition of Synnovation’s experimental treatment aims to expand Novartis' oncology portfolio as well as improve precision medicine options.
J&J completes $3.05B Halda Therapeutics acquisition
The addition of the Connecticut biotech expands Johnson & Johnson's oncology pipeline in prostate cancer and solid tumor treatments.
Shionogi to buy Jersey City pharma for $2.5B
The newly formed company holds the rights to Radicava – a treatment for ALS, also known as Lou Gehrig's disease.
Bristol Myers Squibb to acquire Orbital for $1.5B
The deal expands the Lawrenceville-based biopharmaceutical company's RNA medicine and in vivo CAR T-cell therapy capabilities.
Merck to acquire Verona Pharma in $10B COPD drug deal
The Rahway pharma giant will add FDA-approved treatment Ohtuvayre with the acquisition, helping expand its cardio-pulmonary pipeline and portfolio.
